story of the week
Addition of Everolimus to First-Line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial
JAMA Oncol 2021 Aug 26;[EPub Ahead of Print], Y Fan, T Sun, Z Shao, Q Zhang, Q Ouyang, Z Tong, S Wang, Y Luo, Y Teng, X Wang, S Wang, Q Liu, J Feng, K Shen, Y Song, J Wang, F Ma, Q Li, P Zhang, B XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.